Annovis Bio develops buntanetap, an experimental oral drug for Alzheimer's and Parkinson's disease. ANVS reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 28 | Roth Capital | Target lowered | Buy | |
| Aug 18 | Canaccord Genuity | Maintained | Buy | |
| Jul 8 | Roth Capital | Initiated | Buy |
Seasonality
How ANVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in ANVS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANVS is in one of them and how their past ANVS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ANVS in an article yet. Here's the latest on the wider market.
About Annovis Bio
Annovis Bio is a drug development company focused on neurodegenerative diseases such as Alzheimer's and Parkinson's. Its main product candidate, buntanetap, is an oral small molecule drug designed to lower several harmful proteins linked to nerve cell damage. The company is still in clinical testing and does not yet have an approved product for sale, so its intended customers are patients with these diseases. It is based in Malvern, Pennsylvania.
- Headquarters
- Malvern, PA